A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Scynexis, Inc.2 sites in 1 country96 target enrollmentNovember 2015

Overview

Brief Summary

This is a randomized, multicenter, evaluator blinded study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SCY-078 compared to Fluconazole in adult patients with moderate to severe Vulvovaginal Candidiasis (VVC) and a history of frequent episodes of VVC. Approximately 90 subjects, meeting the inclusion criteria will be enrolled and randomized in a 1:1:1 ratio to one of the 3 treatment arms: Oral SCY-078 in 2 dose regimens or oral Fluconazole. After enrollment, subjects will be evaluated on Day-5 (end of treatment visit), Day-24 (test of cure visit), Day-60, Day 90 and Day 120 (end of observation period visit) or at any time that a recurrence or clinical failure is suspected, up to the end of observation period.

Detailed Description

This is a randomized, multicenter, evaluator blinded study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SCY-078 compared to Fluconazole in adult patients, from 18 to 65 years of age, with moderate to severe Vulvovaginal Candidiasis (VVC) and a history of frequent episodes of VVC. Approximately 90 subjects, meeting the inclusion criteria will be enrolled and randomized in a 1:1:1 ratio to one of the 3 treatment arms: oral SCY-078 does regimen 1, or oral SCY-078 does regimen 2, or oral Fluconazole. After enrollment, subjects will be evaluated on Day-5 (end of treatment visit), Day-24 (test of cure visit), Day-60, Day 90 and Day 120 (end of observation period visit) or at any time that a recurrence or clinical failure is suspected, up to the end of observation period. Primary Objectives: \* To evaluate the safety and efficacy of 2 dosing regimens of Oral SCY-078 in subjects with moderate to severe Vulvovaginal Candidiasis (VVC) Secondary Objectives: \* To estimate the effect of Oral SCY-078 therapy in the rate and time to recurrence in subjects with a history of frequent episodes of VVC

Registry

clinicaltrials.gov

Start Date

November 2015

End Date

August 5, 2016

Last Updated

6 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Scynexis, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must fulfill all of the following criteria to be eligible for study admission:
•Female subjects from 18 to 65 years of age in good general health
•Diagnosis of symptomatic moderate to severe vulvovaginal candidiasis
•The ability to understand and sign a written informed consent form (ICF), which must be obtained prior to treatment and any study-related procedures.
•The ability to understand and sign a consent or authorization form which shall permit the use, disclosure and transfer of the subject's personal health information (e.g., in the U.S. HIPAA Authorization form).
•The ability to understand and follow all study-related procedures including study drug administration.
•Females of childbearing potential must agree to use a medically acceptable method of contraception while receiving protocol-assigned product.

Exclusion Criteria

•A subject will be excluded from participation in the study if she meets any of the following exclusion criteria:
•Any vaginal condition other than VVC that may interfere with the diagnosis or evaluation of response to therapy.
•Prior use of any prohibited medication(s) or procedure(s) within the protocol specified timeframe including:
•a. Systemic and/or topical (vaginal) antifungal treatment, prescription or over the counter, within 30 days of the baseline visit.
•Subjects with history of renal impairment, hepatic impairment or cervical cancer.
•4 Subjects with known hypersensitivity to enfumafungin derivatives, fluconazole or any of the components of the formulation.
•HIV infection, chemotherapy or illness serious enough to induce an immune deficiency.